
L2 Diagnostics LLC (AKA: L-Two Diagnostics LLC) Profile last edited on: 2/10/2020
CAGE: 43BA5
UEI: GKA7VH5LFR25
Business Identifier: Candidate biomarkers in diagnosis of Lyme disease, ETBF, and diabetes. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 03
County: New Haven
Congr. District: 03
County: New Haven
Public Profile
L2 Diagnostics is a private biotechnology firm spinoff from The Yale School of Medicine Lyme/Lupus Diagnostics Laboratory. L2 Diagnostics is developing new diagnostic methods that will help distinguish patients infected with Lyme disease from those who have been vaccinated. The firm has broadened its scope of R&D into disease biomarkers and therapies. The firm is identified as working to develop diagnostics and therapeutics and to be located Department of Internal Medicine, Yale School of Medicine
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 1 | NIH | $299,878 | |
Project Title: Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches | ||||
2024 | 1 | NIH | $299,969 | |
Project Title: The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya | ||||
2024 | 1 | NIH | $298,362 | |
Project Title: A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens | ||||
2024 | 1 | NIH | $299,933 | |
Project Title: A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor | ||||
2023 | 2 | NIH | $2,562,068 | |
Project Title: A Novel Vaccine Against Mosquito-Borne Zika Virus Based on Mosquito Salivary Gland Protein AGBR1 |
Key People / Management
Martin J Mattessich -- President
Karen G Anthony
Linda Bockenstedt
Nathalie Marie Bonafe
Michael Cappello
Erol Fikrig
Kevan C Herold
Raymond Morris Johnson
Barbara I Kazmierczak
Raymond A Koski
Michel E Ledizet
Mark J Mamula
Yorgo Modis
Saraspadee Mootien
Saraspadee Mootien
Sukanya Narasimhan
Elizabeth Peterson-Roth
Diane Mcmahon Pratt
Elizabeth P Roth
Alan Sutherland
Sahar Usmani-Brown
Sahar Usmanibrown
Narendra Wajapeyee
Jason Weinstein
Adam Wisnewski
Karen G Anthony
Linda Bockenstedt
Nathalie Marie Bonafe
Michael Cappello
Erol Fikrig
Kevan C Herold
Raymond Morris Johnson
Barbara I Kazmierczak
Raymond A Koski
Michel E Ledizet
Mark J Mamula
Yorgo Modis
Saraspadee Mootien
Saraspadee Mootien
Sukanya Narasimhan
Elizabeth Peterson-Roth
Diane Mcmahon Pratt
Elizabeth P Roth
Alan Sutherland
Sahar Usmani-Brown
Sahar Usmanibrown
Narendra Wajapeyee
Jason Weinstein
Adam Wisnewski